Landscape Capital Management L.L.C. Buys 23,594 Shares of CVS Health Co. (NYSE:CVS)

Landscape Capital Management L.L.C. lifted its stake in CVS Health Co. (NYSE:CVS) by 45.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 75,524 shares of the pharmacy operator’s stock after buying an additional 23,594 shares during the period. Landscape Capital Management L.L.C.’s holdings in CVS Health were worth $4,749,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assetmark Inc. increased its holdings in shares of CVS Health by 9.7% in the third quarter. Assetmark Inc. now owns 410,001 shares of the pharmacy operator’s stock valued at $25,781,000 after purchasing an additional 36,132 shares in the last quarter. Cullinan Associates Inc. grew its holdings in shares of CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock valued at $7,125,000 after acquiring an additional 37,395 shares in the last quarter. Deerfield Management Company L.P. Series C bought a new stake in CVS Health during the second quarter worth $57,584,000. Oppenheimer Asset Management Inc. lifted its position in shares of CVS Health by 5.7% in the third quarter. Oppenheimer Asset Management Inc. now owns 448,323 shares of the pharmacy operator’s stock valued at $28,191,000 after buying an additional 24,285 shares during the last quarter. Finally, CX Institutional lifted its stake in shares of CVS Health by 698.0% during the 3rd quarter. CX Institutional now owns 74,609 shares of the pharmacy operator’s stock worth $4,691,000 after buying an additional 65,259 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Trading Up 1.9 %

Shares of CVS Health stock opened at $56.83 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The company’s fifty day simple moving average is $59.18 and its 200-day simple moving average is $58.61. The stock has a market capitalization of $71.52 billion, a PE ratio of 14.42, a P/E/G ratio of 0.94 and a beta of 0.55. CVS Health Co. has a 1-year low of $52.71 and a 1-year high of $83.25.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.01. The firm had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.21 earnings per share. As a group, equities analysts anticipate that CVS Health Co. will post 5.43 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Monday, October 21st were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.68%. The ex-dividend date was Monday, October 21st. CVS Health’s payout ratio is 67.51%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Evercore ISI increased their target price on shares of CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $62.00 target price on shares of CVS Health in a research report on Tuesday, October 1st. Truist Financial restated a “buy” rating and set a $67.00 target price (down previously from $76.00) on shares of CVS Health in a research report on Wednesday. UBS Group increased their target price on CVS Health from $60.00 to $62.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $72.28.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.